|
Market Closed -
Euronext Dublin
00:55:00 29/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 5.950 EUR | 0.00% |
|
-14.39% | -22.73% |
| 10-23 | Malin Corp writes off investee after US FDA drug rejection | AN |
| 08-26 | Malin swings to interim profit as finance income rises and costs fall | AN |
| Market Cap | 25.79M 28.75M 23.85M 21.6M 40.35M 2.74B 40.84M 285M 114M 1.43B 108M 106M 4.55B | P/E 2024 * |
-
| P/E 2025 | -8.37x |
|---|---|---|---|---|---|
| Enterprise Value | 12.89M 14.37M 11.92M 10.8M 20.17M 1.37B 20.41M 143M 56.77M 716M 53.93M 52.79M 2.27B | EV / Sales 2024 |
-
| EV / Sales 2025 | - |
| Free-Float |
63.83% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 week | -14.39% | ||
| Current month | -15.00% | ||
| 1 month | -15.00% | ||
| 3 months | -16.20% | ||
| 6 months | -25.16% | ||
| Current year | -22.73% |
| 1 week | 5.95 |  | 6.9 |
| 1 month | 5.95 | | 7 |
| Current year | 5.95 | | 8.45 |
| 1 year | 5.95 | | 9.3 |
| 3 years | 3.84 | | 10.4 |
| 5 years | 3.59 | | 10.4 |
| 10 years | 1.4 | | 13.24 |
| Manager | Title | Age | Since |
|---|---|---|---|
Andrea Stafford
DFI | Director of Finance/CFO | 56 | 01/05/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
William Daniel
CHM | Chairman | 73 | 02/08/2019 |
| Director/Board Member | 67 | 16/07/2018 | |
Rudy Mareel
BRD | Director/Board Member | 63 | 16/07/2018 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 2/6/26 | Exercice | 10,307 | 0.2382% | |||
| 28/5/25 | Exercice | Chief Executive Officer | 5,746 | 0.1328% | ||
| 7/4/25 | Sell | Director | 11,075 | 0.2560% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -14.39% | -28.31% | +43.03% | 28.74M | |
| +0.90% | +1.67% | +57.53% | +128.37% | 1,143B | |
| +0.93% | +5.20% | +45.07% | +84.44% | 647B | |
| +0.10% | +0.77% | +26.13% | +102.27% | 506B | |
| -0.05% | +1.73% | +52.74% | +65.27% | 384B | |
| -1.08% | -6.32% | +61.34% | +36.75% | 350B | |
| +0.34% | +1.84% | +30.70% | +52.69% | 293B | |
| -0.45% | +1.19% | +2.89% | +24.92% | 265B | |
| +0.43% | +2.72% | +54.15% | +71.07% | 242B | |
| -0.19% | +3.41% | +34.72% | +104.20% | 197B | |
| Average | +0.11% | -0.68% | +33.69% | +71.30% | 402.76B | |
| Weighted average by Cap. | +0.33% | +0.71% | +44.59% | +87.11% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | - |
| Net income | - | -6.9M -7.69M -6.38M -5.78M -10.79M -732M -10.92M -76.27M -30.38M -383M -28.86M -28.25M -1.22B |
| Net Debt | -62.1M -69.22M -57.41M -52M -97.15M -6.59B -98.32M -686M -273M -3.45B -260M -254M -10.95B | -12.9M -14.38M -11.93M -10.8M -20.18M -1.37B -20.42M -143M -56.8M -717M -53.96M -52.82M -2.27B |
Employees
2
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/10/26 | €5.950 | 0.00% | 42 |
| 27/10/26 | €5.950 | -4.80% | 86 |
| 26/10/26 | €6.250 | 0.00% | 1 |
| 23/10/26 | €6.250 | -9.42% | 1,627 |
| 22/10/26 | €6.900 | -0.72% | 1,064 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
5.950EUR
Average target price
15.50EUR
Spread / Average Target
+160.50%
- Stock Market
- Stocks
- MLC Stock
Select your edition
All financial news and data tailored to specific country editions
